Atypical antipsychotics in the treatment of mood disorders

被引:21
作者
Vieta, E [1 ]
机构
[1] Univ Barcelona, Hosp Clin, Bipolar Disorders Program, IDIBAPS, E-08036 Barcelona, Spain
关键词
atypical antipsychotics; bipolar disorder; depression; mania; mood stabilizer;
D O I
10.1097/00001504-200301000-00006
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of review There is an emerging body of data and clinical experience on the use of atypical antipsychotics in disorders other than schizophrenia, and particularly in the field of mood disorders. The present review addresses the most recent data on the efficacy of these drugs in the treatment of mania, depression and other mood syndromes. Recent findings Recent trials support the efficacy and the safety of most atypical antipsychotics in the treatment of acute mania. Several trials suggest that atypical antipsychotics are as effective as typical antipsychotics, but that they are safer and more efficacious than mood stabilizer monotherapy in the treatment of mania. Recent data also support the use of adjunctive olanzapine in both bipolar and unipolar depression, and there is a suggestion that some atypical antipsychotics may possess mood stabilizing effects. Summary The atypical antipsychotic agents are useful medications for the treatment of mood disorders. There is clear evidence for their efficacy in mania, and data are emerging that suggest that they may also be useful in augmentation treatment of several forms of depression, and even perhaps as prophylaxis.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 54 条
[41]   Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy [J].
Tohen, M ;
Chengappa, KNR ;
Suppes, T ;
Zarate, CA ;
Calabrese, JR ;
Bowden, CL ;
Sachs, GS ;
Kupfer, DJ ;
Baker, RW ;
Risser, RC ;
Keeter, EL ;
Feldman, PD ;
Tollefson, GD ;
Breier, A .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (01) :62-69
[42]  
TOHEN M, 2003, IN PRESS ARCH GEN PS
[43]   Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder [J].
Vieta, E ;
Reinares, M ;
Corbella, B ;
Benabarre, A ;
Gilaberte, I ;
Colom, F ;
Martínez-Arán, A ;
Gastó, C ;
Tohen, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (05) :469-473
[44]   Role of risperidone in bipolar II:: an open 6-month study [J].
Vieta, E ;
Gastó, C ;
Colom, F ;
Reinares, M ;
Martínez-Arán, A ;
Banabarre, A ;
Akiskal, HS .
JOURNAL OF AFFECTIVE DISORDERS, 2001, 67 (1-3) :213-219
[45]   Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders:: Results from a 6-month, multicenter, open study [J].
Vieta, E ;
Goikolea, JM ;
Corbella, B ;
Benabarre, A ;
Reinares, M ;
Martínez, G ;
Fernández, A ;
Colom, F ;
Martínez-Arán, A ;
Torrent, C .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (10) :818-825
[46]   Treatment of refractory rapid cycling bipolar disorder with risperidone [J].
Vieta, E ;
Gasto, C ;
Colom, F ;
Martinez, A ;
Otero, A ;
Vallejo, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (02) :172-174
[47]   Risperidone in the treatment of mania:: efficacy and safety results from a large, multicentre, open study in Spain [J].
Vieta, E ;
Herraiz, M ;
Parramon, G ;
Goikolea, JM ;
Fernández, A ;
Benabarre, A .
JOURNAL OF AFFECTIVE DISORDERS, 2002, 72 (01) :15-19
[48]  
Vieta E, 1995, HUM PSYCHOPHARM CLIN, V10, P491
[49]   Efficacy and safety of risperidone in the treatment of schizoaffective disorder:: Initial results from a large, multicenter surveillance study [J].
Vieta, E ;
Herraiz, M ;
Fernández, A ;
Gastó, C ;
Benabarre, A ;
Colom, F ;
Martínez-Arán, A ;
Reinares, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (08) :623-630
[50]   Quetiapine in the treatment of rapid cycling bipolar disorder [J].
Vieta, E ;
Parramon, G ;
Padrell, E ;
Nieto, E ;
Martinez-Arán, A ;
Corbella, B ;
Colom, F ;
Reinares, M ;
Goikolea, JM ;
Torrent, C .
BIPOLAR DISORDERS, 2002, 4 (05) :335-340